GCG and type 2 diabetes mellitus: Various clinical trials are ongoing for the assessment of the effectiveness of GLP-1 RAs, especially semaglutide, liraglutide and exenatide, on CVD and atherosclerosis in patients with or without T2DM and obesity (Table 2).